NCT03818412 Circulating Tumor DNA in Soft Tissue Sarcoma
| NCT ID | NCT03818412 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Soft Tissue Sarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2019-01-17 |
| Primary Completion | 2026-12-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2019-01-17 with a primary completion date of 2026-12-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
Eligibility Criteria
Inclusion Criteria: * Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma. * Patients must have archival tissue from the diagnostic biopsy available. * Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist. * Age 18 years or older. * Eastern Cooperative Group (ECOG) performance status ≤ 2 * Ability to understand and willing to sign a written informed consent document and comply with study requirements. Exclusion Criteria: * Patients with benign histology * Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix. * Patients with planned neo-adjuvant chemotherapy. * Patients with regional nodal disease or unequivocal metastases * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Contact & Investigator
Albiruni Razak, M.D.
PRINCIPAL INVESTIGATOR
Princess Margaret Cancer Centre
Frequently Asked Questions
Who can join the NCT03818412 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Soft Tissue Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03818412 currently recruiting?
Yes, NCT03818412 is actively recruiting participants. Contact the research team at albiruni.razak@uhn.ca for enrollment information.
Where is the NCT03818412 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT03818412 clinical trial?
NCT03818412 is sponsored by University Health Network, Toronto. The principal investigator is Albiruni Razak, M.D. at Princess Margaret Cancer Centre. The trial plans to enroll 40 participants.